Ordr Partners with e-Quip to Deliver Improved Connected Medical Device Visibility and Security for UK Healthcare Market

Combined Solution Provides the Real-Time Insight and Detailed Information Needed to Properly Manage and Secure the Increasing Number of Connected Medical Devices

Ordr, the leader in connected device security, today announced it has partnered with the UK’s leading medical device asset management provider Integra e-Quip Ltd. The two companies have teamed up to deliver a best-in-class clinical asset management and security solution to healthcare organizations throughout the UK.

e-Quip’s Computerised Maintenance Management System (CMMS) maintains an inventory of all connected medical devices on a network, orchestrating critical processes such as device maintenance, procurement planning, and compliance assurance. Ordr’s AI-powered platform automatically discovers and classifies all devices connecting to a network, including IoMT (Internet of Medical Things) devices. The insights delivered by Ordr help teams identify and understand potential device risks like the presence of obsolete operating systems, manufacturer recalls, vulnerabilities, weak passwords, or outdated certificates.

Ordr is critical to address a number of UK compliance initiatives including:

NHS Trust Data Security Protection Toolkit (DSPT) compliance
Cyber Essentials
NIS2 Directive

The integration between e-Quip and Ordr enables clinical engineering departments and IT teams to have real-time, granular visibility into all connected medical devices, ensuring that the e-Quip CMMS always remains up-to-date with accurate details. Ordr helps with the challenging activity of asset reconciliation – identifying authorized medical devices in the e-Quip system that are not on the network, or discovering deployed devices that are not in the CMMS. This is critical for real-time inventory, and to prioritize vulnerabilities and schedule patch management in clinical settings. In addition, with Ordr’s strong capabilities in behavioral baselining and threat detection, the combined solution can identify devices that are behaving abnormally, automatically initiating the correct e-Quip workflows to address these risks.

“Integra e-Quip is dedicated to making it easy for healthcare organizations to manage the myriad of medical devices they have connected to their networks. Doing this efficiently and effectively requires advanced visibility,” said Dal Jdali, CEO, at Integra e-Quip. “By teaming with Ordr we can provide customers with that real-time analysis of connected devices, helping them gain an accurate understanding of their attack surface – and the ability to identify and address potential risks.”

Ordr’s platform enables clinical engineering and IT teams across NHS trusts to not only discover and classify every connected device in the hospital, but also identify medical devices that have critical vulnerabilities that need to be patched. Armed with this information, the e-Quip system can then schedule and prioritize patching efforts, ensuring teams are up to date with potential risks across their environment – and are mitigating any risks in a timely manner.

“The global healthcare industry faces a unique set of challenges when it comes to managing and securing its connected devices,” added Pandian Gnanprakasam, co-founder and Chief Product Officer, Ordr. “Every NHS Trust is responsible for protecting all the connected devices operating in their networks whether they are aware of them or not. Ordr discovers, identifies, and assesses all of an organization’s connected assets giving healthcare security teams a comprehensive view into the activities of each device on their network, and a full understanding of the risks each pose. With operating systems being brought to end-of-life and devices not manufactured with security in mind, it is critical for teams to have the tools to access risk and quickly apply security policy protections.”

e-Quip CMMS is used across the U.K. by many National Health Services (NHS) trusts and their clinical engineering teams. The combined solution addresses the challenges NHS Trusts face in managing and securing the growing number of connected medical devices that today’s healthcare organizations have come to depend upon.

For more information about how Ordr and e-Quip can help your organization discover and secure every connected medical device, please click here.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

“The completion of the APEX-AV Study represents an important milestone in the catheter-directed therapies CDT space for the treatment of pulmonary embolism. I sincerely thank all the investigators for their commitment and dedication,” said William Brent Keeling, MD, Associate Professor of Surgery, Department of Surgery, at the Emory University School of Medicine, and Immediate Past President, The PERT Consortium™.
The combined expertise of Cordance Medical and the Airan and Williams Labs will see NeuroAccess utilized to deliver a novel application of drug-loaded nanoparticles, providing targeted drug delivery to the brain.
Medixine prepares for 2024 with two key senior hires, VP of Operations in the U.S. and VP of Engineering in Finland. The appointments will enhance support and service to the company’s U.S.-based partners, including leading respiratory homecare provider Lincare and a major medical device manufacturer. In addition, the new hires will enable streamlined design, testing, and deployment of new product features for more patient-centric, cost and time-effective treatment of chronic conditions.
Innovent Biologics and Synaffix: Under the terms of the expanded agreement, Innovent will be responsible for the research, development, manufacturing and commercialization of new ADC candidates. Synaffix is eligible to receive an upfront payment plus potentialmilestone payments and royalties on commercial sales for each licensed target.
Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.

By using this website you agree to accept Medical Device News Magazine Privacy Policy